Diabetes KOL Luncheon with CEO Butler, COO Erdtmann and CMO Frias at the WCIRDC Congress (ahead of the ASH Annual Meeting) to be held in Los Angeles on December 8 at 2 pm hosted by Oppenheimer.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMEA:
- Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
- Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes
- Biomea Fusion announces Health Canada Clearance of CTA for BMF-219
- Citi opens ‘positive catalyst watch’ on Biomea Fusion into data
- Biomea Fusion announces acceptance of three abstracts for COVALENT-111 trial